ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.83 USD 4.57%
Market Cap: 176.9m USD

ADC Therapeutics SA
Investor Relations

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Show more
Loading

Earnings Calls

2024 Q3
Nov 7, 2024
Show Transcript
Previous
Next
Strong Performance Drives Future Growth Prospects for ADC Therapeutics
2024 Q3
Nov 7, 2024

In Q3 2024, ADC Therapeutics reported net product revenues of $18 million, up from $14.3 million a year ago, highlighting ongoing strength in ZYNLONTA sales totaling $52.9 million year-to-date. Enrollment in their LOTIS-5 study nears completion, with expectations for data release by late 2025. The company remains focused on expanding ZYNLONTA’s use in earlier treatment lines for DLBCL and indolent lymphomas, aiming for potential peak sales exceeding $80 million. A disciplined capital allocation strategy has reduced operating expenses by 12% year-over-year, ensuring continued investment in key initiatives despite a net loss of $44 million for the quarter.

Show Full Analysis

Management

Dr. Ameet Mallik M.B.A., M.S.
CEO & Director
No Bio Available
Mr. Jose I. Carmona M.B.A.
Chief Financial Officer
No Bio Available
Dr. Mohamed Zaki M.D., Ph.D.
Chief Medical Officer
No Bio Available
Ms. Lisa Michelle Kallebo
Corporate Controller & Chief Accounting Officer
No Bio Available
Dr. Michael Mulkerrin Ph.D.
Chief Technical Operations Officer
No Bio Available
Dr. Patrick van Berkel Ph.D.
Chief Scientific Officer
No Bio Available
Amanda Hamilton
Investor Relations Officer
No Bio Available
Mr. Peter J. Graham Esq.
Secretary & Chief Legal Officer
No Bio Available
Ms. Eugenia Litz
Vice President of Investor Relations & Corporate Communications
No Bio Available
Ms. Kimberly Pope
Senior VP & Chief People Officer
No Bio Available

Contacts

Address
VAUD
Epalinges
Biopole, route de la Corniche 3B
Contacts
+41216530200.0
adctherapeutics.com